The Novo Nordisk Foundation, the Broad Institute of MIT and Harvard have launched an initiative to gain insights into disease mechanisms.
In an effort to accelerate efforts to mine genetic data for insights into mechanisms, and eventually rationally designed treatments, the trio of entities launched the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease based at the Broad Institute in Cambridge, Massachusetts.
Get the full story at our sister site, Drug Delivery Business News.
Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin.
Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The retail price of analog insulin vials will be $72.88, while a FlexPen insulin pen will cost $85.88. Walmart has concluded that the per-unit savings of the products will be $101 per vial and $251 per insulin pen, respectively.
The insulin will only be available through Walmart’s ReliOn brand of diabetes products.
Get the full story from our sister site, Drug Delivery Business.
Milpitas, Calif.-based Bigfoot’s first-of-its-kind Bigfoot Unity system features connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
Two international clinical trials published today in Diabetes Care found that the once-weekly treatment has the potential to offer a convenient alternative to daily insulin shots for those with type 2 diabetes, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
Two international clinical trials published today in Diabetes Care found that the once-weekly treatment has the potential to offer a convenient alternative to daily insulin shots for those with type 2 diabetes, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance.
Now ranked eighth overall, the pharma industry came in just ahead of the consumer services industry and just behind the automobiles and components sector.
Get the full story from our sister site, Pharmaceutical Processing World.